Dr. M. Chance Spalding brings a decade of leadership in life-saving trauma and critical care medicine. Additionally, he brings deep experience in clinical quality improvement, pREBOA-PRO™ programs, and teaching to lead Prytime Medical's global, clinical strategy.
SAN ANTONIO, Jan. 19, 2024 /PRNewswire-PRWeb/ -- Prytime Medical Devices Inc, The REBOA Company™, the leading innovator and global provider of lifesaving REBOA products for minimally invasive, endovascular hemorrhage control and resuscitation, announced today the hiring of Chief Medical Officer, M. Chance Spalding, D.O., Ph.D., F.A.C.S.
"I'm excited to join Prytime Medical at this important time in its growth and evolution. I've seen how partial REBOA using the pREBOA-PRO™ catheter gives me time to treat patients who are severely hypotensive," said Dr. Spalding. "Over the past two and a half years, I've worked with other physicians in the REBOA Centers of Excellence program to better understand the clinical value of partial REBOA using pREBOA-PRO™," continued Spalding. "Within those Centers, there is an emerging consensus being published of how this technology can change our practice to save more lives. First, by breaking the 30-minute Zone 1 barrier, it buys more time to treat the patient. ¹, ², ³, ⁴, ⁵, ⁶ Second, the additional time expands our treatment options allowing us to get diagnostic data from imaging, perform more endovascular-only procedures, and reduce OR procedures and blood product usage.⁶, ⁷, ⁸ Finally, we're seeing reduced complications like acute kidney injury." ⁹, ¹⁰, ¹¹, ¹², ¹³
"I'm excited that Dr. Spalding has chosen to join Prytime's mission: No one should bleed to death, and the sooner you stop the bleeding, the better," said David Spencer CEO. "Time is the enemy of the trauma surgeon. 57% of their REBOA cases are longer than 30 minutes. In 2021, Prytime Medical launched the pREBOA-PRO™ catheter designed to enable True Partial REBOA™ and give physicians more time to treat," continued Spencer. "We developed a programmatic approach to implementing REBOA focused on three key principles: team training and development, institutional guidelines, and process improvement. These REBOA Excellence Programs are supported by a field team focused on Fanatical Clinical Support™ and Fanatical Program Support™ to help our customers be successful. Adding one of the most experienced pREBOA-PRO™ surgeons to our team like Dr. Spalding ensures that the physician's voice is always central to our scientific evidence development, customer training and support, and continued market growth."
"As a PhD in Biomedical Engineering, I'm passionate about the intersection of technology and medicine," continued Spalding. I've seen in my own practice how the pREBOA-PRO™ catheter gives me more time and options to save my patients. I look forward to working with the trauma community to realize the promise that this technology has to improve our patients' outcomes."
M. Chance Spalding, D.O., Ph.D., F.A.C.S. is a physician-scientist and trauma surgeon who has launched two pREBOA-PRO™ Centers of Excellence. He currently serves as the Director of the Surgical and Trauma Intensive Care Unit at the Mount Carmel Health System in Columbus, Ohio. Dr. Spalding received his Doctor of Osteopathic Medicine at Ohio University and his PhD at the University of Pittsburgh. He completed a Surgical Critical Care Fellowship at Parkland, UT Southwestern. Dr. Spalding has authored or co-authored over 75 peer-reviewed journal articles including 16 REBOA articles. He performed the first commercial pREBOA-PRO™ patient case in 2021. Dr. Spalding has led and participated in over 100 clinical research single-site and multi-center studies. He has been a frequent speaker, lecturer, and trainer on partial REBOA using pREBOA-PRO™. In 2023, Dr. Spalding traveled to Ukraine to train military physicians on partial REBOA.
About Prytime Medical Devices, Inc.
Prytime Medical™ Devices, Inc. is an innovative medical device company that designs, develops, and commercializes minimally invasive solutions for hemorrhage control. Our latest innovations, the industry leading ER-REBOA PLUS™, and the innovative pREBOA-PRO™ partial REBOA catheter, enable torso hemorrhage control with more controlled resuscitation in a much wider range of clinical scenarios. pREBOA-PRO™ is the first and only FDA-cleared REBOA catheter designed specifically for True Partial REBOA™. More information can be found at http://www.PrytimeMedical.com
Notes:
1 Prytime Medical Centers' of Excellence. Data on file.
2 Polcz et al., (2022) J Surg Res. Based on preclinical data. Clinical results in humans are unknown.
3 Edwards et al., (2022) J Am Coll Surg. Clinical results in humans are unknown.
4 Necsoiu et al., (2021) Shock. Based on preclinical data. Clinical results in humans are unknown.
5 Kemp et al., (2021) J Trauma Acute Care Surg. Based on preclinical data. Clinical results in humans are unknown.
6 Ho et al., (2023) J Trauma Acute Care Surg. Clinical results in humans are unknown.
7 Nguyen et al., (2023), Maximizing patient care: Partial REBOA enables increased use of CT imaging and endovascular hemorrhage control, AAST poster
8 Nguyen et el., (2024), pREBOA vs ER-REBOA Impact on Blood Utilization and Resuscitation Requirements: A Pilot Analysis, EAST presentation
9 Russo et al., (2020) J Trauma Acute Care Surg.
10 Gomez et al., (2023) J Trauma Acute Care Surg.
11 Ronaldi et al., (2021) Shock. Based on preclinical data. Clinical results in humans are unknown.
12 Madurska et al., (2021) Eur J Trauma Emerg Surg.
13 Hunt et al., (2023) The American Surgeon
Media Contact
Jeff Jung, Prytime Medical Devices, Inc, 2105441752, [email protected], prytimemedical.com
SOURCE Prytime Medical Devices, Inc
Share this article